tiprankstipranks
Trending News
More News >
Micro-X Ltd. (AU:MX1)
ASX:MX1
Australian Market

Micro-X Ltd. (MX1) AI Stock Analysis

Compare
5 Followers

Top Page

AU

Micro-X Ltd.

(Sydney:MX1)

Rating:41Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
The overall stock score for Micro-X Ltd. is primarily impacted by its financial performance, which shows moderate revenue growth but significant challenges in achieving profitability and positive cash flow. Technical analysis further reinforces a bearish outlook with negative momentum indicators. The valuation score is low due to negative profitability metrics.

Micro-X Ltd. (MX1) vs. iShares MSCI Australia ETF (EWA)

Micro-X Ltd. Business Overview & Revenue Model

Company DescriptionMicro-X Limited designs, develops, and manufactures lightweight carbon nano tube-based X-ray products for the healthcare and security imaging markets in Australia. The company offers rover veterinary, a mobile X-ray machine to diagnose and treat animals for general veterinarian practices; Carestream DRX Revolution Nano, a mobile X-ray imaging machine used for high intensity workflow diagnostic medical imaging in hospitals; and IED X-ray cameras. It also provides miniature baggage scanners to detect hidden threats concealed within passenger carry-on luggage; airport screening reimagined, a passenger self-screening airport checkpoint; and brain CT scanners for use in road and air ambulances. The company was incorporated in 2011 and is based in Tonsley, Australia.
How the Company Makes MoneyMicro-X Ltd. generates revenue primarily through the sale of its advanced X-ray imaging products. The company's key revenue streams include direct sales to healthcare facilities, such as hospitals and clinics, and sales to government agencies and private enterprises in the security sector. Additionally, Micro-X engages in partnerships and collaborations with industry leaders to enhance its product offerings and expand its market reach. The company's earnings are further supported by ongoing research and development efforts aimed at broadening its product portfolio and maintaining a competitive edge in the rapidly evolving imaging technology market.

Micro-X Ltd. Financial Statement Overview

Summary
Micro-X Ltd. is experiencing moderate revenue growth but faces challenges in profitability and cash flow. The balance sheet shows stability with low leverage, but the lack of profitability impacts return metrics.
Income Statement
45
Neutral
Micro-X Ltd. has shown a moderate revenue growth rate of 1.45% over the past year, reflecting a slight improvement. However, the company is still facing challenges in terms of profitability, with negative net and gross profit margins. The EBIT and EBITDA margins are also negative, indicating operational difficulties in achieving profitable growth.
Balance Sheet
55
Neutral
The company has a relatively low debt-to-equity ratio of 0.28, suggesting conservative leverage, which is a positive. However, the return on equity is negative due to net losses, indicating inefficiencies in generating returns from shareholders' equity. The equity ratio of 53.03% highlights a stable capital structure with a significant portion of assets financed by equity.
Cash Flow
40
Negative
Micro-X Ltd. shows negative free cash flow growth, highlighting ongoing challenges in generating positive cash flow. The operating cash flow to net income ratio is negative, indicating struggles in converting operations into cash. However, the company has managed to secure financing, which provides some liquidity support.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
14.43M15.22M15.01M8.97M3.77M4.25M
Gross Profit
6.19M5.74M-7.11M-12.33M-12.96M-7.69M
EBIT
1.65M-13.03M-16.30M-19.77M-15.83M-11.69M
EBITDA
-15.75M-14.35M-14.71M-19.02M-13.61M-9.29M
Net Income Common Stockholders
-10.78M-9.77M-10.75M-17.09M-14.73M-10.07M
Balance SheetCash, Cash Equivalents and Short-Term Investments
4.38M3.23M5.22M10.30M30.14M18.32M
Total Assets
13.54M26.89M30.30M31.28M44.68M33.70M
Total Debt
6.75M3.99M4.77M5.38M5.90M13.54M
Net Debt
2.38M762.00K-455.00K-4.92M-24.23M-4.77M
Total Liabilities
13.70M12.63M13.17M12.05M10.53M18.96M
Stockholders Equity
-165.00K14.26M17.13M19.22M34.15M14.74M
Cash FlowFree Cash Flow
-9.22M-6.80M-11.77M-19.22M-10.76M-11.65M
Operating Cash Flow
-9.07M-6.43M-10.99M-18.11M-9.86M-9.46M
Investing Cash Flow
-152.00K-369.00K-779.00K-1.11M-901.00K-2.20M
Financing Cash Flow
6.31M4.81M6.69M-612.00K22.57M28.37M

Micro-X Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.05
Price Trends
50DMA
0.06
Negative
100DMA
0.07
Negative
200DMA
0.07
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
14.10
Positive
STOCH
-19.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MX1, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 14.10 is Positive, neither overbought nor oversold. The STOCH value of -19.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:MX1.

Micro-X Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AURHT
61
Neutral
AU$18.38M140.00-3.11%89.13%69.57%
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
AUEMV
48
Neutral
AU$151.79M-58.61%-74.88%
AUAR9
47
Neutral
AU$19.29M-45.31%-28.80%32.87%
AUMX1
41
Neutral
AU$34.03M-135.33%-27.58%33.69%
$13.79M-467.81%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:MX1
Micro-X Ltd.
0.05
-0.04
-44.44%
CDEXF
CardieX Limited
0.36
0.00
0.00%
AU:RHT
Resonance Health Ltd
0.04
-0.02
-33.33%
AU:AR9
archTIS Ltd.
0.07
-0.02
-22.22%
AU:EMV
EMvision Medical Devices Ltd.
1.78
-0.16
-8.25%

Micro-X Ltd. Corporate Events

Micro-X Ltd. Appoints New Company Secretary to Enhance Growth
May 30, 2025

Micro-X Ltd. has announced the appointment of Mr. Richard Willson as the new Company Secretary, effective May 30, 2025. Mr. Willson brings over 25 years of experience in the technology and resources sectors, with a strong background in corporate governance and financial management. This strategic appointment is expected to strengthen Micro-X’s corporate governance and support its growth ambitions in the health and security markets. The company continues to innovate in x-ray technology and expand its market presence, with significant projects underway in both healthcare and security sectors.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.21 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Ltd. Announces Quotation of New Securities on ASX
May 14, 2025

Micro-X Ltd. has announced the quotation of 171,819 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code MX1, effective from May 15, 2025. This move is part of an employee incentive scheme and reflects the company’s ongoing efforts to enhance its market presence and operational capabilities.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.21 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Ltd. Director Increases Stake Through Share Placement
May 8, 2025

Micro-X Ltd. announced a change in the director’s interest, with Patrick O’Brien acquiring 1,428,571 ordinary shares, increasing his total holdings to 10,287,591 shares. This acquisition was made through a company placement approved by shareholders, reflecting confidence in the company’s strategic direction and potential growth, which could impact stakeholders positively by enhancing market confidence.

Micro-X Director Increases Stake with Significant Share Acquisition
May 8, 2025

Micro-X Ltd. announced a change in the director’s interest, with Ilona Meyer acquiring 357,143 ordinary shares through a company placement approved by shareholders. This acquisition increases Meyer’s total holdings to 567,961 fully paid ordinary shares, indicating a significant investment in the company’s future, potentially impacting its market positioning and stakeholder confidence.

Micro-X Director Increases Stake, Signaling Confidence in Growth
May 8, 2025

Micro-X Ltd. announced a change in the director’s interest, with Jim McDowell acquiring 714,286 ordinary shares through the company’s placement approved at the Extraordinary General Meeting in April 2025. This acquisition increases McDowell’s indirect holding, indicating a vote of confidence in the company’s strategic direction and potential growth, which could positively impact stakeholders and market perception.

Micro-X Director Increases Stake with Share Acquisition
May 8, 2025

Micro-X Ltd. announced a change in the director’s interest, with Director Andrew Hartmann acquiring 357,143 fully paid ordinary shares valued at $25,000. This acquisition was part of a company placement approved by shareholders, potentially strengthening the director’s alignment with company interests and signaling confidence in Micro-X’s future growth.

Micro-X Ltd. Announces Quotation of New Securities on ASX
May 7, 2025

Micro-X Ltd. has announced the quotation of 2,857,143 ordinary fully paid securities on the Australian Securities Exchange (ASX) with the code MX1, set to be issued on May 8, 2025. This move is part of previously announced transactions and is expected to enhance the company’s market presence and provide additional capital for its operations, potentially impacting its industry positioning and stakeholder interests.

Micro-X Ltd. Approves Key Resolutions at Extraordinary General Meeting
Apr 16, 2025

Micro-X Ltd. held an Extraordinary General Meeting on April 16, 2025, where several resolutions regarding the ratification and approval of the issuance of placement shares were passed. These resolutions, which received overwhelming support, are part of the company’s strategic initiatives to strengthen its financial position and expand its market presence.

Micro-X Ltd. Announces Cessation of Performance Rights
Apr 7, 2025

Micro-X Ltd. announced the cessation of 1,167,220 performance rights due to the lapse of conditional rights that were not satisfied. This cessation may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s operational performance and strategic execution.

Micro-X Ltd. Announces New Share Issuance on ASX
Mar 20, 2025

Micro-X Ltd. announced the issuance of 8,836,524 fully paid ordinary shares, which will be quoted on the ASX. This move is part of previously announced transactions and could potentially strengthen the company’s financial position, enhancing its market presence and providing additional resources for growth and development.

Micro-X Ltd Completes Retail Entitlement Offer, Strengthening Financial Position
Mar 19, 2025

Micro-X Ltd announced the completion of its Retail Entitlement Offer, raising approximately $0.62 million, contributing to a total of $6.4 million in new funds from various capital raising initiatives. This financial boost strengthens Micro-X’s balance sheet, supporting its strategic execution in commercial and development products within medical imaging, and highlights the significant shareholder support crucial for the company’s ongoing success.

Micro-X Ltd. Announces Extraordinary General Meeting Following Successful Capital Raising
Mar 14, 2025

Micro-X Ltd. has announced an Extraordinary General Meeting scheduled for April 16, 2025, to discuss resolutions related to a recent capital raising initiative. The company successfully raised $6.0 million through various placements, including a strategic partnership with Billion Prima Sdn Bhd and institutional placements, to strengthen its financial position and support future growth. The meeting will address the refreshment of the company’s placement capacity and the issuance of shares to related parties, reflecting a strategic move to bolster its market presence and operational capabilities.

Micro-X Ltd. Concludes Retail Entitlement Offer to Bolster Market Position
Mar 12, 2025

Micro-X Ltd. has announced the closing of its Retail Entitlement Offer on 14 March 2025, allowing eligible shareholders to apply for new shares at a price of A$0.07 each. This offer, which includes a ‘top-up’ facility for additional shares, aims to strengthen the company’s financial position and support its ongoing projects in health and security markets. The outcome of this offer could significantly impact Micro-X’s operations and market positioning, providing capital for further development of their innovative x-ray products and expansion into new applications.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.